Biosimilars: More Treatment Options Are on the Way
As the medical market grows, the US Food and Drug Administration FDA has published a neat piece about biosimilars. Recently, FDA has approved a second biosimilar product—Inflectra (Infliximab-dyyb), a biosimilar to Remicade (infliximab)—and expects to approve other biosimilars in the future.